Bristol-Myers Squibb (NYSE:BMY) Trades 1% Higher

Bristol-Myers Squibb (NYSE:BMY – Get Free Report ) traded up 1% during trading on Friday. The stock traded as high as $41.87 and last traded at $41.43. 3,974,292 shares were traded mid-day, down 74% from the session’s average volume of 15,410,671 shares. Shares previously closed at $41.04.

Changes in Analyst Ratings

Several analysts have recently commented on the stock. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Barclays decreased their price objective on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 17th. BMO Capital Markets reduced their price objective on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday, April 26th . Finally, Wells Fargo & Company upped their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a report on Thursday. April 18. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $60.00, based on data from MarketBeat.com.

Get the latest research report on Bristol-Myers Squibb

Bristol-Myers Squibb trading rose 2.2%

The stock has a market cap of $85.00 billion, a price-to-earnings ratio of -13.53, a PEG ratio of 13.89 and a beta of 0.43. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11, and a quick ratio of 0.99. The company’s 50-day simple moving average is $43.60, and its two-hundred-day simple moving average is $48.43.

Bristol-Myers Squibb (NYSE:BMY – Get Your Free Report ) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. The firm had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. Bristol-Myers Squibb’s revenue was up 4.7% compared to the same quarter last year. During the same period last year, the company posted earnings of $2.05 per share. On average, research analysts anticipate that Bristol-Myers Squibb will post 0.59 earnings per share for the current fiscal year.

Bristol-Myers Squibb announces dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, July 5. This represents a dividend of $2.40 on an annualized basis and a yield of 5.72%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Institutional inputs and outputs

Institutional investors have recently made changes to their positions in the company. ESL Trust Services LLC purchased a new position in shares of Bristol-Myers Squibb in the first quarter worth $27,000. Northwest Financial Advisors purchased a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at $27,000. Accordant Advisory Group Inc purchased a new position in shares of Bristol-Myers Squibb in the first quarter worth $31,000. Pacific Capital Wealth Advisors Inc. acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at $34,000. Finally, VisionPoint Advisory Group LLC lifted its position in shares of Bristol-Myers Squibb by 300.5% during the third quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 553 shares during the last quarter. 76.41% of shares are owned by institutional investors and hedge funds.

About Bristol-Myers Squibb

(Get a free report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic and neuroscience. The company’s products include Eliquis for reducing the risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anticancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

See also

Get news and reviews for Bristol-Myers Squibb Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.